Table 2.
The Results from Univariate Analysis for Recurrence Outcome
| Variables | ER Group (n= 694) | Non-ER Group (n= 643) | P value |
|---|---|---|---|
| Gendera | 0.031 | ||
| Female | 123 (17.72%) | 146 (22.71%) | |
| Male | 571 (82.28%) | 497 (77.29%) | |
| Etiologya | 0.003 | ||
| None | 92 (13.26%) | 130 (20.22%) | |
| HBV | 537 (77.38%) | 456 (70.92%) | |
| HCV | 62 (8.93%) | 52 (8.09%) | |
| Alcohol-induced | 3 (0.43%) | 5 (0.78%) | |
| Number of tumorsa | <0.001 | ||
| 1 | 345 (49.71%) | 488 (75.89%) | |
| 2 | 213 (30.69%) | 118 (18.35%) | |
| 3 | 136 (19.60%) | 37 (5.75%) | |
| Abutting organsa | 0.030 | ||
| None | 370 (53.31%) | 359 (55.83%) | |
| Gastrointestinal tract | 63 (9.08%) | 36 (5.60%) | |
| Gallbladder | 48 (6.92%) | 23 (3.58%) | |
| Hilum hepatis | 4 (0.58%) | 10 (1.56%) | |
| Large vessels | 51 (7.35%) | 64 (9.95%) | |
| Bile duct | 8 (1.15%) | 5 (0.78%) | |
| Diaphragm | 75 (10.81%) | 72 (11.20%) | |
| Liver surface | 68 (9.80%) | 69 (10.73%) | |
| Pericardium | 7 (1.01%) | 5 (0.78%) | |
| Tumor locationa | 0.013 | ||
| Left | 157 (22.62%) | 146 (22.71%) | |
| Right | 537 (77.38%) | 497 (77.29%) | |
| Comorbidity scorea | 0.034 | ||
| Low | 432 (62.25%) | 426 (66.25%) | |
| High | 262 (37.75%) | 217 (33.75%) | |
| AST (U/L) | 0.013 | ||
| >40 | 454 (65.40%) | 321 (49.90%) | <0.001 |
| ≤40 | 240 (34.60%) | 322 (51.10%) | |
| AFP (ng/mL) | <0.001 | ||
| >400 | 305 (62.25%) | 156 (66.25%) | |
| ≤400 | 389 (37.75%) | 487 (33.75%) | |
| γ-GGT (U/L) | 0.003 | ||
| >60 | 415 (59.80%) | 332 (51.60%) | |
| ≤60 | 279 (40.20%) | 311 (48.40%) | |
| AKP (U/L) | <0.001 | ||
| >150 | 521 (75.10%) | 211 (32.80%) | |
| ≤150 | 173 (24.90%) | 432 (67.20%) | |
| TBIL (umol/mL) | <0.001 | ||
| >17.1 | 483 (69.60%) | 335 (52.10%) | |
| ≤17.1 | 211 (30.40%) | 308 (47.90%) | |
| BIL (umol/mL) | 0.049 | ||
| >7.0 | 384 (55.00%) | 388 (60.30%) | |
| ≤7.0 | 314 (45.00%) | 255 (39.70%) | |
| CHE (U/L) | <0.001 | ||
| >4000 | 512 (73.80%) | 387 (60.20%) | |
| ≤4000 | 182 (26.20%) | 256 (39.80%) | |
| WBC (X109) | 0.004 | ||
| >4.0 | 488 (70.30%) | 404 (62.80%) | |
| ≤4.0 | 206 (29.70%) | 239 (37.20%) | |
| PLT (X109) | <0.001 | ||
| >100 | 492 (62.25%) | 418 (66.25%) | |
| ≤100 | 202 (37.75%) | 225 (33.75%) | |
| NEU (X109) | 0.021 | ||
| >400 | 432 (70.90%) | 426 (65.00%) | |
| ≤400 | 262 (29.10%) | 217 (35.00%) | |
| PT (s) | 0.004 | ||
| >15 | 468 (67.40%) | 385 (59.90%) | |
| ≤15 | 226 (32.60%) | 258 (40.10%) |
Notes: aData are frequencies with percentages in parentheses; P value<0.05 indicated a significant difference.
Abbreviations: HCC, hepatocellular carcinoma; IR, intrahepatic recurrence; HBV, hepatitis B virus; HCV, hepatitis C virus; AST, aspartate aminotransferase; AFP, α-fetoprotein; γ-GT, gamma glutamyltransferase; AKP, alkaline phosphatase; TBIL, total bilirubin; BIL, bilirubin; CHE, cholinesterase; NEU, neutrophils; PT, prothrombin time.